Oncolytics Biotech (ONCY) Updates on Registration Plan for REOLYSIN; Will Initially Focus on Two Indications
Tweet Send to a Friend
Oncolytics Biotech (NASDAQ: ONCY) provided an update on its planned registration program for REOLYSIN, its proprietary formulation of the human ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
